iSTAR Medical announced today that the FDA granted investigational device exemption to start a pivotal trial with its MINIject implant.
Wavre, Belgium-based iStar’s MINIject minimally invasive implant for glaucoma surgery will be investigated in the STAR-V study, which will enroll over 350 patients with primary open-angle glaucoma.
Get the full story at our sister site, Drug Delivery Business News.